|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
Nifedipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Nifedipine results in decreased activity of ABCB11 protein |
CTD |
PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
ISO |
Nifedipine results in increased expression of ABCB1 protein |
CTD |
PMID:8632764 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
EXP |
Nifedipine results in increased expression of ABCC2 mRNA |
CTD |
PMID:12206135 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases activity increases expression multiple interactions |
ISO |
Nifedipine results in increased activity of ABCC3 protein Nifedipine results in increased expression of ABCC3 mRNA [Nifedipine results in increased activity of NR1I2 protein] which results in increased expression of ABCC3 mRNA |
CTD |
PMID:14570758 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression multiple interactions |
ISO |
Nifedipine results in decreased expression of AKT1 protein modified form 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin promotes the reaction [[Nifedipine co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein]]; [Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of AKT1 protein; Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]; Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of AKT1 protein]; Wortmannin inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]]; Wortmannin inhibits the reaction [Simvastatin promotes the reaction [[Nifedipine co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein]] |
CTD |
PMID:20530298 PMID:20562903 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apoa1 |
apolipoprotein A1 |
increases expression |
ISO |
Nifedipine results in increased expression of APOA1 |
CTD |
PMID:1928808 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apoa2 |
apolipoprotein A2 |
increases expression |
ISO |
Nifedipine results in increased expression of APOA2 |
CTD |
PMID:1928808 |
|
NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355
|
|
G |
Avp |
arginine vasopressin |
multiple interactions |
EXP |
Nifedipine inhibits the reaction [AVP protein results in increased import of and results in increased abundance of Calcium] |
CTD |
PMID:14711191 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP ISO |
Nifedipine inhibits the reaction [Gentamicins results in increased expression of BAX protein] Nifedipine inhibits the reaction [DMD gene mutant form results in increased expression of BAX mRNA] |
CTD |
PMID:19698708 PMID:24349043 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
Nifedipine results in decreased expression of BCL2 Nifedipine inhibits the reaction [Gentamicins results in decreased expression of BCL2 protein] Nifedipine results in increased expression of and affects the localization of BCL2 protein |
CTD |
PMID:10075388 PMID:10695937 PMID:19698708 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
EXP |
Nifedipine inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of BDNF protein] |
CTD |
PMID:11279263 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Cacna1c |
calcium voltage-gated channel subunit alpha1 C |
affects response to substance multiple interactions |
ISO |
CACNA1C protein affects the susceptibility to Nifedipine Nifedipine inhibits the reaction [[Potassium Chloride co-treated with CACNA1C protein alternative form] results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:18441296 PMID:20128810 |
|
NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
multiple interactions |
EXP ISO |
Nifedipine inhibits the reaction [FPL 64176 promotes the reaction [CAMK2A protein binds to DRD3 protein]] Nifedipine inhibits the reaction [Cocaine results in increased expression of and results in increased phosphorylation of CAMK2A protein] |
CTD |
PMID:19217379 PMID:28194001 |
|
NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
Nifedipine inhibits the reaction [alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid inhibits the reaction [Phencyclidine results in increased activity of CASP3 protein]]; Nifedipine inhibits the reaction [Methamphetamine results in increased cleavage of CASP3 protein] |
CTD |
PMID:24995437 PMID:26923100 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Clu |
clusterin |
multiple interactions |
EXP |
Nifedipine inhibits the reaction [methoxyacetic acid results in increased expression of and results in increased secretion of CLU protein] |
CTD |
PMID:14656996 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP ISO |
Nifedipine inhibits the reaction [Nicotine results in increased phosphorylation of CREB1 protein] Nifedipine inhibits the reaction [[Potassium Chloride co-treated with CACNA1C protein alternative form] results in increased phosphorylation of CREB1 protein] Nifedipine inhibits the reaction [Potassium Chloride results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:20128810 PMID:21113126 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Csn2 |
casein beta |
decreases expression multiple interactions |
ISO |
Nifedipine results in decreased expression of CSN2 mRNA Nifedipine promotes the reaction [Cadmium results in decreased expression of CSN2 mRNA] |
CTD |
PMID:21167921 |
|
NCBI chr14:20,322,581...20,329,818
Ensembl chr14:20,322,581...20,329,817
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Nifedipine results in decreased activity of CYP1A1 protein |
CTD |
PMID:18420780 PMID:33814510 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity multiple interactions |
ISO EXP |
Nifedipine results in decreased activity of CYP1A2 protein Nifedipine inhibits the reaction [CYP1A2 protein results in increased metabolism of 3-cyano-7-ethoxycoumarin] |
CTD |
PMID:10805063 PMID:18420780 PMID:19858067 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Nifedipine results in decreased activity of CYP1B1 protein |
CTD |
PMID:18420780 PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
decreases activity |
ISO |
Nifedipine results in decreased activity of CYP2A4 protein |
CTD |
PMID:18420780 |
|
NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
decreases activity |
ISO |
Nifedipine results in decreased activity of CYP2B10 protein |
CTD |
PMID:18420780 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
multiple interactions |
EXP |
Nifedipine promotes the reaction [Cyclosporine results in increased expression of CYP2C11 protein] |
CTD |
PMID:28899749 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c66 |
cytochrome P450, family 2, subfamily c, polypeptide 66 |
decreases activity |
ISO |
Nifedipine results in decreased activity of CYP2C9 protein |
CTD |
PMID:18420780 |
|
NCBI chr 1:237,078,517...237,169,841
Ensembl chr 1:237,078,517...237,169,650
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases activity |
ISO |
Nifedipine results in decreased activity of CYP2C8 protein Nifedipine results in decreased activity of CYP2C29 protein |
CTD |
PMID:15601807 PMID:18420780 |
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases activity |
ISO |
Nifedipine results in decreased activity of CYP2D6 protein |
CTD |
PMID:18420780 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity |
ISO |
Nifedipine results in decreased activity of CYP2E1 protein |
CTD |
PMID:18420780 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
decreases activity |
ISO |
Nifedipine results in decreased activity of CYP2J2 protein |
CTD |
PMID:30965050 |
|
NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions affects metabolic processing increases metabolic processing increases expression affects oxidation increases hydroxylation increases oxidation |
EXP ISO |
[SOD2 co-treated with CYP3A4] affects the susceptibility to Nifedipine; Nifedipine inhibits the reaction [CYP3A2 protein results in increased metabolism of 7-benzyloxyquinoline] CYP3A4 protein affects the metabolism of Nifedipine CYP3A4 protein results in increased metabolism of Nifedipine 6',7'-dihydroxybergamottin inhibits the reaction [CYP3A4 protein results in increased oxidation of Nifedipine]; [Nifedipine binds to CYP3A4 promoter] which results in decreased expression of CYP3A4 mRNA; [Nifedipine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [Nifedipine results in increased expression of CYP3A4 mRNA]]; Cimetidine inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Nifedipine]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Nifedipine]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased oxidation of Nifedipine]; Nifedipine inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]; NR1I2 protein promotes the reaction [Nifedipine results in increased expression of CYP3A4 mRNA]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased oxidation of Nifedipine]; YM 758 inhibits the reaction [CYP3A4 protein results in increased metabolism of Nifedipine] Nifedipine results in increased expression of CYP3A4 mRNA; Nifedipine results in increased expression of CYP3A4 protein CYP3A4 protein affects the oxidation of Nifedipine |
CTD |
PMID:2271712 PMID:12851153 PMID:15286053 PMID:15618748 PMID:15634941 PMID:15784650 PMID:15937564 PMID:16712844 PMID:16837568 PMID:17041008 PMID:17954527 PMID:18846481 PMID:19230594 PMID:19299527 PMID:19501153 PMID:19858067 PMID:20863320 PMID:22524704 PMID:23146034 PMID:25069801 More...
|
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
increases expression |
EXP |
Nifedipine results in increased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:16125621 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
EXP |
Nifedipine inhibits the reaction [Oxygen deficiency results in increased expression of DDIT3 mRNA]; Nifedipine inhibits the reaction [Oxygen deficiency results in increased expression of DDIT3 protein] |
CTD |
PMID:22226148 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dmd |
dystrophin |
multiple interactions |
ISO |
Nifedipine inhibits the reaction [DMD gene mutant form results in increased abundance of Calcium]; Nifedipine inhibits the reaction [DMD gene mutant form results in increased expression of BAX mRNA]; Nifedipine inhibits the reaction [DMD gene mutant form results in increased expression of NOS2 mRNA]; Nifedipine inhibits the reaction [DMD gene mutant form results in increased secretion of Adenosine Triphosphate] |
CTD |
PMID:24349043 |
|
NCBI chr X:47,272,324...49,504,219
Ensembl chr X:47,272,331...49,504,207
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
EXP |
Nifedipine inhibits the reaction [DRD2 protein affects the reaction [Quinpirole results in decreased transport of Barium]] |
CTD |
PMID:11124974 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Drd3 |
dopamine receptor D3 |
multiple interactions |
EXP |
Nifedipine inhibits the reaction [FPL 64176 promotes the reaction [CAMK2A protein binds to DRD3 protein]] |
CTD |
PMID:19217379 |
|
NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596
|
|
G |
Edn1 |
endothelin 1 |
decreases activity multiple interactions increases activity |
EXP |
Nifedipine results in decreased activity of EDN1 protein Nifedipine inhibits the reaction [Isoproterenol results in increased activity of EDN1 promoter] Nifedipine results in increased activity of EDN1 protein |
CTD |
PMID:7528292 PMID:11435416 PMID:12628492 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
Nifedipine inhibits the reaction [Oxygen deficiency results in increased expression of EIF2AK3 mRNA]; Nifedipine inhibits the reaction [Oxygen deficiency results in increased expression of EIF2AK3 protein] |
CTD |
PMID:22226148 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
multiple interactions |
EXP |
Nifedipine affects the reaction [Haloperidol results in increased phosphorylation of ELK1 protein] |
CTD |
PMID:17913375 |
|
NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713
|
|
G |
Esr1 |
estrogen receptor 1 |
increases activity |
ISO |
Nifedipine results in increased activity of ESR1 protein |
CTD |
PMID:25257666 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
affects response to substance multiple interactions |
ISO |
Nifedipine affects the susceptibility to FGF2 protein Nifedipine inhibits the reaction [FGF2 protein results in increased expression of FOS mRNA] |
CTD |
PMID:15141722 PMID:16188231 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
increases secretion increases expression |
ISO |
Nifedipine results in increased secretion of FGF7 protein Nifedipine results in increased expression of FGF7 mRNA |
CTD |
PMID:11023675 |
|
NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases expression |
ISO EXP |
Nifedipine inhibits the reaction [FGF2 protein results in increased expression of FOS mRNA] [Nifedipine co-treated with omega-Conotoxin GVIA co-treated with omega-Agatoxin IVA] inhibits the reaction [Potassium Chloride affects the expression of FOS mRNA]; Nifedipine affects the reaction [Haloperidol results in increased expression of FOS protein]; Nifedipine inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of FOS protein]; Nifedipine inhibits the reaction [Hexachlorocyclohexane results in increased expression of FOS protein]; Nifedipine inhibits the reaction [Pentylenetetrazole results in increased expression of FOS protein] Nifedipine results in decreased expression of FOS protein |
CTD |
PMID:7534335 PMID:16188231 PMID:17913375 PMID:20211981 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
EXP |
Nifedipine inhibits the reaction [diphenylditelluride results in decreased phosphorylation of GFAP protein] |
CTD |
PMID:21863293 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
multiple interactions |
ISO |
Nifedipine inhibits the reaction [Cocaine results in increased expression of and results in increased phosphorylation of GRIA1 protein] |
CTD |
PMID:28194001 |
|
NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
Nifedipine inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:23769903 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Hdac4 |
histone deacetylase 4 |
affects localization |
EXP |
Nifedipine affects the localization of HDAC4 protein |
CTD |
PMID:20559781 |
|
NCBI chr 9:92,503,467...92,750,164
Ensembl chr 9:92,507,611...92,750,164
|
|
G |
Hgf |
hepatocyte growth factor |
increases expression |
ISO |
Nifedipine results in increased expression of HGF protein |
CTD |
PMID:15071489 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
Nifedipine results in increased expression of HMOX1 protein |
CTD |
PMID:21525764 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnmt |
histamine N-methyltransferase |
decreases activity |
EXP |
Nifedipine results in decreased activity of HNMT protein |
CTD |
PMID:2408645 |
|
NCBI chr 3:6,591,804...6,623,821
Ensembl chr 3:6,591,463...6,624,012
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
increases activity |
ISO |
Nifedipine results in increased activity of HSF1 protein |
CTD |
PMID:34170685 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
Nifedipine inhibits the reaction [Oxygen deficiency results in increased expression of HSPA5 mRNA]; Nifedipine inhibits the reaction [Oxygen deficiency results in increased expression of HSPA5 protein] |
CTD |
PMID:22226148 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Igf1 |
insulin-like growth factor 1 |
decreases response to substance |
ISO |
Nifedipine results in decreased susceptibility to IGF1 protein |
CTD |
PMID:16485066 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igf2 |
insulin-like growth factor 2 |
decreases response to substance |
ISO |
Nifedipine results in decreased susceptibility to IGF2 protein |
CTD |
PMID:16485066 |
|
NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
Nifedipine results in increased expression of IL1B mRNA |
CTD |
PMID:28138970 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Ins1 |
insulin 1 |
multiple interactions decreases expression |
EXP |
Nifedipine inhibits the reaction [Quercetin results in increased secretion of INS1 protein] Nifedipine results in decreased expression of INS1 protein |
CTD |
PMID:7564366 PMID:23530660 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Kcna1 |
potassium voltage-gated channel subfamily A member 1 |
multiple interactions |
EXP |
[Nifedipine co-treated with omega-Conotoxin GVIA co-treated with omega-Agatoxin IVA] promotes the reaction [Potassium Chloride results in increased expression of KCNA1 mRNA] |
CTD |
PMID:20211981 |
|
NCBI chr 4:159,464,223...159,472,905
Ensembl chr 4:159,464,188...159,472,682
|
|
G |
Kcna3 |
potassium voltage-gated channel subfamily A member 3 |
decreases activity |
ISO |
Nifedipine results in decreased activity of KCNA3 protein |
CTD |
PMID:17638537 |
|
NCBI chr 2:194,632,106...194,634,059
Ensembl chr 2:194,632,196...194,650,138
|
|
G |
Kcnc3 |
potassium voltage-gated channel subfamily C member 3 |
multiple interactions |
EXP |
[Nifedipine co-treated with omega-Conotoxin GVIA co-treated with omega-Agatoxin IVA] inhibits the reaction [Potassium Chloride results in increased expression of KCNC3 mRNA] |
CTD |
PMID:20211981 |
|
NCBI chr 1:95,080,960...95,095,165
Ensembl chr 1:95,080,960...95,095,160
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Nifedipine inhibits the reaction [nickel chloride results in increased phosphorylation of MAPK1 protein] Nifedipine affects the reaction [Ptychodiscus brevis T2 toxin affects the phosphorylation of MAPK1 protein] |
CTD |
PMID:15086530 PMID:25045119 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Nifedipine inhibits the reaction [nickel chloride results in increased phosphorylation of MAPK3 protein] Nifedipine affects the reaction [Ptychodiscus brevis T2 toxin affects the phosphorylation of MAPK3 protein] |
CTD |
PMID:15086530 PMID:25045119 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
Nifedipine results in decreased expression of and results in decreased activity of MMP9 protein |
CTD |
PMID:18204791 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression |
ISO |
Nifedipine results in increased expression of MYC protein |
CTD |
PMID:10695937 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myh10 |
myosin heavy chain 10 |
decreases expression |
ISO EXP |
Nifedipine results in decreased expression of MYH10 protein |
CTD |
PMID:20530298 |
|
NCBI chr10:53,393,901...53,525,174
Ensembl chr10:53,394,389...53,525,165
|
|
G |
Myh11 |
myosin heavy chain 11 |
increases expression |
ISO EXP |
Nifedipine results in increased expression of MYH11 protein |
CTD |
PMID:20530298 |
|
NCBI chr10:743,364...838,459
Ensembl chr10:743,685...838,459
|
|
G |
Myh7 |
myosin heavy chain 7 |
decreases response to substance |
ISO |
MYH7 gene mutant form results in decreased susceptibility to Nifedipine |
CTD |
PMID:29741611 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Myl9 |
myosin light chain 9 |
decreases phosphorylation |
EXP |
Nifedipine results in decreased phosphorylation of MYL9 protein |
CTD |
PMID:17272349 |
|
NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
multiple interactions |
ISO |
Nifedipine inhibits the reaction [Glucose results in increased secretion of NAMPT protein] |
CTD |
PMID:23536823 |
|
NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
|
|
G |
Nefl |
neurofilament light chain |
multiple interactions |
EXP |
Nifedipine inhibits the reaction [diphenylditelluride results in decreased phosphorylation of NEFL protein] |
CTD |
PMID:21863293 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nefm |
neurofilament medium chain |
multiple interactions |
EXP |
Nifedipine inhibits the reaction [diphenylditelluride results in decreased phosphorylation of NEFM protein] |
CTD |
PMID:21863293 |
|
NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects localization |
ISO |
Nifedipine affects the localization of NFE2L2 protein |
CTD |
PMID:21525764 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP |
Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:23583884 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
EXP |
Nifedipine inhibits the reaction [NGF protein results in increased uptake of Calcium] |
CTD |
PMID:1374475 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Nifedipine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] Nifedipine inhibits the reaction [DMD gene mutant form results in increased expression of NOS2 mRNA] |
CTD |
PMID:11245857 PMID:24349043 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of and results in increased expression of NOS3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of and results in increased expression of NOS3 protein]]; [Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of and results in increased expression of NOS3 protein; Nifedipine inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]; Nifedipine inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 mRNA]; Nifedipine inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 protein]; Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of and results in increased expression of NOS3 protein]; Nifedipine promotes the reaction [Simvastatin inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]]; Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of and results in increased expression of NOS3 protein]; Simvastatin promotes the reaction [Nifedipine inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]]; Simvastatin promotes the reaction [Nifedipine inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 mRNA]]; Simvastatin promotes the reaction [Nifedipine inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 protein]]; wortmannin inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of and results in increased expression of NOS3 protein]]; wortmannin inhibits the reaction [Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of and results in increased expression of NOS3 protein]] |
CTD |
PMID:20562903 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nppa |
natriuretic peptide A |
decreases expression |
ISO |
Nifedipine results in decreased expression of NPPA mRNA |
CTD |
PMID:20559781 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions |
EXP |
[Losartan co-treated with Nifedipine] results in decreased expression of NPPB mRNA |
CTD |
PMID:17666919 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions decreases activity |
ISO |
Nifedipine inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] Nifedipine results in decreased activity of NR1H4 protein |
CTD |
PMID:25257666 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
[Nifedipine results in increased activity of NR1I2 protein] which results in increased expression of ABCC3 mRNA; [Nifedipine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [Nifedipine results in increased expression of CYP3A4 mRNA]]; Nifedipine binds to and results in increased activity of NR1I2 protein; NR1I2 protein promotes the reaction [Nifedipine results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:14570758 PMID:17041008 PMID:21291553 PMID:25069801 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
decreases expression |
ISO |
Nifedipine results in decreased expression of OLR1 mRNA |
CTD |
PMID:12072588 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Pdcd4 |
programmed cell death 4 |
decreases expression |
ISO |
Nifedipine results in decreased expression of PDCD4 mRNA |
CTD |
PMID:21873647 |
|
NCBI chr 1:252,921,342...252,944,278
Ensembl chr 1:252,921,392...252,944,275
|
|
G |
Pla2g4a |
phospholipase A2 group IVA |
multiple interactions |
ISO EXP |
[Nifedipine co-treated with 2-aminoethoxydiphenyl borate] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G4A mRNA]; Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G4A mRNA] |
CTD |
PMID:18938131 PMID:19162293 PMID:23583884 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Prl |
prolactin |
multiple interactions |
EXP |
Nifedipine inhibits the reaction [bisphenol A results in increased secretion of PRL protein]; Nifedipine inhibits the reaction [Coumestrol results in increased secretion of PRL protein]; Nifedipine inhibits the reaction [Dieldrin results in increased secretion of PRL protein]; Nifedipine inhibits the reaction [Diethylstilbestrol results in increased secretion of PRL protein]; Nifedipine inhibits the reaction [Endosulfan results in increased secretion of PRL protein]; Nifedipine inhibits the reaction [Estradiol results in increased secretion of PRL protein]; Nifedipine inhibits the reaction [nonylphenol results in increased secretion of PRL protein]; Nifedipine inhibits the reaction [o,p'-DDT results in increased secretion of PRL protein] |
CTD |
PMID:15811834 PMID:17174995 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO EXP |
[Nifedipine co-treated with 2-aminoethoxydiphenyl borate] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]; Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA] arachidonyltrifluoromethane promotes the reaction [Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]]; Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA] |
CTD |
PMID:18388244 PMID:18938131 PMID:19063610 PMID:23583884 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and affects the localization of RELA protein] |
CTD |
PMID:23583884 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ren |
renin |
multiple interactions increases expression increases activity |
ISO |
[Dexamethasone co-treated with Nifedipine co-treated with Atenolol co-treated with Antihypertensive Agents] results in increased secretion of REN protein; Angiotensin-Converting Enzyme Inhibitors promotes the reaction [Nifedipine results in increased activity of REN protein]; Nifedipine promotes the reaction [Angiotensin-Converting Enzyme Inhibitors results in increased activity of REN protein] Nifedipine results in increased expression of REN protein |
CTD |
PMID:3142437 PMID:3313686 PMID:3326920 PMID:6184561 PMID:6354932 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
RT1-Bb |
RT1 class II, locus Bb |
affects expression |
ISO |
Nifedipine affects the expression of HLA-DQB1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,596,558...4,602,201
Ensembl chr20:4,596,559...4,607,597
|
|
G |
Scn5a |
sodium voltage-gated channel alpha subunit 5 |
decreases activity |
EXP |
Nifedipine results in decreased activity of SCN5A protein |
CTD |
PMID:16331678 PMID:17978865 |
|
NCBI chr 8:119,220,905...119,318,816
Ensembl chr 8:119,220,905...119,318,769
|
|
G |
Serpinb2 |
serpin family B member 2 |
multiple interactions |
ISO |
Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SERPINB2 mRNA] |
CTD |
PMID:18388244 |
|
NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
multiple interactions |
ISO |
Nifedipine promotes the reaction [SLC10A1 protein results in increased uptake of Indocyanine Green] |
CTD |
PMID:32209977 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
multiple interactions |
EXP |
Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of SLC1A2 protein] |
CTD |
PMID:26988466 |
|
NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO |
Nifedipine inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:21641380 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions |
ISO |
Nifedipine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:21641380 |
|
NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
|
|
G |
Slc22a4 |
solute carrier family 22 member 4 |
multiple interactions |
ISO |
Nifedipine inhibits the reaction [SLC22A4 protein results in increased uptake of Tetraethylammonium] |
CTD |
PMID:21641380 |
|
NCBI chr10:38,133,333...38,179,932
Ensembl chr10:38,133,322...38,179,720
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
multiple interactions |
ISO |
Nifedipine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] |
CTD |
PMID:21641380 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G |
Slc23a2 |
solute carrier family 23 member 2 |
multiple interactions |
ISO |
Nifedipine inhibits the reaction [Calcium results in increased expression of SLC23A2 mRNA]; Nifedipine inhibits the reaction [Phosphates results in increased expression of SLC23A2 mRNA] |
CTD |
PMID:12788230 |
|
NCBI chr 3:119,302,651...119,395,289
Ensembl chr 3:119,302,666...119,460,343
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases expression affects response to substance |
EXP ISO |
[SOD2 co-treated with CYP3A4] affects the susceptibility to Nifedipine Nifedipine results in increased expression of SOD2 mRNA; Nifedipine results in increased expression of SOD2 protein SOD2 protein affects the susceptibility to Nifedipine |
CTD |
PMID:18327084 PMID:19501153 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
ISO |
Nifedipine inhibits the reaction [Calcium results in increased expression of SPP1 mRNA]; Nifedipine inhibits the reaction [Phosphates results in increased expression of SPP1 mRNA] |
CTD |
PMID:12788230 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
EXP ISO |
Nifedipine inhibits the reaction [Oxygen deficiency results in decreased expression of STAR mRNA]; Nifedipine inhibits the reaction [Oxygen deficiency results in decreased expression of STAR protein] Nifedipine promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA] |
CTD |
PMID:19822634 PMID:22226148 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
[Losartan co-treated with Nifedipine] results in decreased expression of TGFB1 mRNA |
CTD |
PMID:17666919 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TNF mRNA]; Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased secretion of TNF protein] |
CTD |
PMID:23583884 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
decreases expression |
ISO |
Nifedipine results in decreased expression of TNFAIP3 mRNA |
CTD |
PMID:21873647 |
|
NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282
|
|
G |
Tp53 |
tumor protein p53 |
increases activity |
ISO |
Nifedipine results in increased activity of TP53 protein |
CTD |
PMID:12082016 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpd52 |
tumor protein D52 |
increases expression |
ISO |
Nifedipine results in increased expression of TPD52 mRNA |
CTD |
PMID:21873647 |
|
NCBI chr 2:92,735,365...92,816,079
Ensembl chr 2:92,735,620...92,816,622
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
[Nifedipine co-treated with 2-aminoethoxydiphenyl borate] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA]; Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA] arachidonyltrifluoromethane promotes the reaction [Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA]] |
CTD |
PMID:18388244 PMID:18938131 PMID:19063610 PMID:19162293 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vim |
vimentin |
multiple interactions |
EXP |
Nifedipine inhibits the reaction [diphenylditelluride results in decreased phosphorylation of VIM protein] |
CTD |
PMID:21863293 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|